Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,100 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS, Schwartz JH, Gundapaneni B, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Multicenter Study
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
Fontana M, Berk JL, Gillmore JD, et al. · N Engl J Med · 2025Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
Adams D, Tournev IL, Taylor MS, et al. · Amyloid · 2023Randomized Controlled Trial
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.
Gillmore JD, Judge DP, Cappelli F, et al. · N Engl J Med · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.
Antonopoulos AS, Panagiotopoulos I, Kouroutzoglou A, et al. · Eur J Heart Fail · 2022Meta-Analysis, Systematic Review
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
Gillmore JD, Gane E, Taubel J, et al. · N Engl J Med · 2021Clinical Trial, Phase I, Multicenter Study
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Multicenter Study
- Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.
Benson MD, Waddington-Cruz M, Berk JL, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Multicenter Study
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
Maurer MS, Kale P, Fontana M, et al. · N Engl J Med · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy.
Maurer MS, Judge DP, Gillmore JD, et al. · J Am Coll Cardiol · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Hereditary transthyretin-related amyloidosis.
Finsterer J, Iglseder S, Wanschitz J, et al. · Acta Neurol Scand · 2019Systematic Review
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
Judge DP, Heitner SB, Falk RH, et al. · J Am Coll Cardiol · 2019Randomized Controlled Trial, Research Support, N.I.H., Extramural
- CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy.
Fontana M, Solomon SD, Kachadourian J, et al. · N Engl J Med · 2024Clinical Trial, Phase I
- Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
Judge DP, Gillmore JD, Alexander KM, et al. · Circulation · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis.
Facin LC, Romeiro IPF, Sapahia K, et al. · Arq Bras Cardiol · 2025Systematic Review, Meta-Analysis
- Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
Judge DP, Alexander KM, Cappelli F, et al. · J Am Coll Cardiol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.
Damy T, Wang R, Maurer MS, et al. · Eur J Heart Fail · 2025Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Damy T, Garcia-Pavia P, Hanna M, et al. · Eur J Heart Fail · 2021Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
Coelho T, Maia LF, Martins da Silva A, et al. · Neurology · 2012Clinical Trial, Phase II, Multicenter Study
- Amyloid-Specific Medication in Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis of Cardiovascular Outcome trials.
Autherith M, Hauptmann L, Koschatko S, et al. · J Card Fail · 2026Systematic Review, Meta-Analysis
- Inotersen treatment for ATTR amyloidosis.
Benson MD · Amyloid · 2019Clinical Trial, Phase III, Randomized Controlled Trial
- Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
Masri A, Maurer MS, Claggett BL, et al. · J Card Fail · 2024Clinical Trial, Phase III, Multicenter Study
- Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.
Garcia-Pavia P, Aus dem Siepen F, Donal E, et al. · N Engl J Med · 2023Clinical Trial, Phase I, Randomized Controlled Trial
- Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Habtemariam BA, Karsten V, Attarwala H, et al. · Clin Pharmacol Ther · 2021Clinical Trial, Phase I, Randomized Controlled Trial
- Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Gillmore JD, Gane E, Täubel J, et al. · N Engl J Med · 2025Clinical Trial, Phase I, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.